WO1994014071A1 - Methode de diagnostic des tumeurs malignes chez l'etre humain - Google Patents

Methode de diagnostic des tumeurs malignes chez l'etre humain Download PDF

Info

Publication number
WO1994014071A1
WO1994014071A1 PCT/UA1993/000007 UA9300007W WO9414071A1 WO 1994014071 A1 WO1994014071 A1 WO 1994014071A1 UA 9300007 W UA9300007 W UA 9300007W WO 9414071 A1 WO9414071 A1 WO 9414071A1
Authority
WO
WIPO (PCT)
Prior art keywords
κροvi
smear
calcium
hours
humans
Prior art date
Application number
PCT/UA1993/000007
Other languages
English (en)
Russian (ru)
Inventor
Evgeny Ivanovich Suslov
Konstantin Alexandrovich Galakhin
Vitaly Alexandrovich Vladimirov
Original Assignee
Novik, Anatoly Matveevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/454,208 priority Critical patent/US5795785A/en
Application filed by Novik, Anatoly Matveevich filed Critical Novik, Anatoly Matveevich
Priority to PCT/UA1993/000007 priority patent/WO1994014071A1/fr
Priority to EP94904064A priority patent/EP0674177A4/fr
Priority to AU58264/94A priority patent/AU5826494A/en
Publication of WO1994014071A1 publication Critical patent/WO1994014071A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Definitions

  • ⁇ dna ⁇ is ⁇ lz ⁇ vanie b ⁇ lshins ⁇ va izves ⁇ ny ⁇ me ⁇ d ⁇ v s ⁇ inig ⁇ v ⁇ y diagn ⁇ s ⁇ i ⁇ i na ⁇ avlen ⁇ on
  • the most efficient methods in this direction are those based on the general purpose of the research. 2 markers in the biological fluids of the body, in particular, in the region.
  • the task posed is solved in that with the help of the diagnosis of malignant human patients, based on the identification in the field 3 ⁇ bsleduem ⁇ g ⁇ bel ⁇ vy ⁇ ⁇ a ⁇ tsy, s ⁇ etsi ⁇ ichny ⁇ for zl ⁇ aches ⁇ venn ⁇ g ⁇ ⁇ s ⁇ a, s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu in ⁇ tsesse analysis g ⁇ vya ⁇ maz ⁇ ⁇ vi, vzya ⁇ y, ⁇ eimusches ⁇ venn ⁇ from ⁇ altsa ⁇ bsleduem ⁇ g ⁇ and ⁇ sled ⁇ va ⁇ eln ⁇ nan ⁇ sya ⁇ on neg ⁇ ⁇ as ⁇ v ⁇ ⁇ m ⁇ le ⁇ s ⁇ na, s ⁇ anda ⁇ nuyu syv ⁇ u ⁇ vi and
  • the concentration of the device was selected in the range from 1% to 25%. It has been found that the concentration 4 of the unit is less than 1% significantly lengthens during the reaction, and with a concentration of more than 25% - the structure (occupancy) is less frequently shared.
  • the product was used with an acid-base concentrate with a concentration of 0.5% 0.1%.
  • the device is less than 1, 5 is inadequate for the loss of payment, and for more than 3, the loss of power is required. 20 And finally, according to one of the aspects of the present invention, it may be optimal to choose an option during operation. In fact, with an increase in light for more than 4 hours, there is a tendency to overwhelm the structure, and less than 2 hours there is an inadequate reduction in the cost of service.
  • the patented method consists in the following:
  • the investigated one has a bright and brown or red color, but in the middle and central areas the color is not very intense.
  • the resulting result test ifies to the presence in the organism of the investigated malignant disease.
  • Example 5 A smear of patient C was taken, taken from the finger at the time of surgery on the small gland (sectoral resection).
  • Example 6 A smear was delivered from the finger of the patient Ts., With an expectation of a malignant tumor.
  • the spots are divided, which has a light-red primary zone. Occurrence of a spot of dark-brown colors with washed out fuses merges into the middle and central spaces, resulting in a homogeneous part with irregular chambers. Compared to the 30 obtained cases, the differences are observed in terms of quality and distinction, which indicates the presence in the country 9 Investigated malignant process. When a business is found, a second-hand business is discovered.
  • the spots are divided, which has a bright and red area. Occurrence of a spot of dark-brown color 15 with washed out fusions merges in the middle and central spaces, resulting in a homogeneous part with irregular bones. Compared to the previous case, expressed differences in quality and distinction are observed, which indicates that there is negligent negligence in the organization. There were more than 20 large excisions made in the health of children.
  • the histological conclusion is melanoma.
  • a smear of the patient L. was delivered, who treated a gynecologist with complaints of extra-vaginal discharge from the vagina. 25 In a smear, 0.3 ml of a 15% solution of EG 93 handlesvice was applied, then also 0.3 ml of a standard serum mixture was added and, after a short time, 0.2 ml of a 0.5% solution was added. The process of applying the reagents was carried out on light. The results were evaluated after 4 hours.
  • the developed method for diagnosing malignant human injuries is not automatic, highly informative, and is simple to use. This method may be used to diagnose all forms of malignant neoplasms. High Diagnostic 12 sensitivities of 89.4% and a specificity of 86% are considered to be impractical for scoring malignant neoplasms in the population.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette méthode de diagnostic des tumeurs malignes chez l'être humain concerne le domaine de la médecine et, plus spécifiquement, celui de l'oncologie clinique. Cette méthode prévoit la procédure suivante: une solution de complexone est appliquée à un frottis de sang prélevé sur le patient, un sérum sanguin standard est ensuite ajouté et un développeur des complexes calcium-albumine est ensuite appliqué; après un certain laps de temps, la couleur et la structure de la coloration résultante sont comparées avec ce que l'on obtient selon la même procédure avec un échantillon de sang prélevé sur un individu sain, toute différence révélant la présence d'une tumeur maligne dans l'organisme du patient. L'invention précise les proportions optimales diverses des différents réactifs utilisés, permettant d'obtenir la plus grande fiabilité possible dans les résultats.
PCT/UA1993/000007 1992-12-10 1993-12-03 Methode de diagnostic des tumeurs malignes chez l'etre humain WO1994014071A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/454,208 US5795785A (en) 1992-12-10 1993-03-12 Method for the diagnosis of human malignant tumors
PCT/UA1993/000007 WO1994014071A1 (fr) 1992-12-10 1993-12-03 Methode de diagnostic des tumeurs malignes chez l'etre humain
EP94904064A EP0674177A4 (fr) 1992-12-10 1993-12-03 Methode de diagnostic des tumeurs malignes chez l'etre humain.
AU58264/94A AU5826494A (en) 1992-12-10 1993-12-03 Method of diagnosing malignant tumours in humans

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UA93030251 1992-12-10
UA92030251 1992-12-10
PCT/UA1993/000007 WO1994014071A1 (fr) 1992-12-10 1993-12-03 Methode de diagnostic des tumeurs malignes chez l'etre humain

Publications (1)

Publication Number Publication Date
WO1994014071A1 true WO1994014071A1 (fr) 1994-06-23

Family

ID=26667095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/UA1993/000007 WO1994014071A1 (fr) 1992-12-10 1993-12-03 Methode de diagnostic des tumeurs malignes chez l'etre humain

Country Status (1)

Country Link
WO (1) WO1994014071A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447545A (en) * 1980-11-03 1984-05-08 New England Deaconess Hospital Bladder cancer detection
CH645728A5 (fr) * 1979-01-30 1984-10-15 Otsuka Pharma Co Ltd Procede de determination de la teneur en substances contenant des liaisons glucosidiques associees aux tumeurs, application de ce procede et necessaire pour sa mise en oeuvre.
SU1305556A1 (ru) * 1983-04-18 1987-04-23 Киевский Научно-Исследовательский Институт Туберкулеза И Грудной Хирургии Им.Ф.Г.Яновского Способ определени дифференцирующихс клеток на препарате
EP0254081A2 (fr) * 1986-06-30 1988-01-27 Yuko Yoneda Procédé pour détecter une protéine spécifique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH645728A5 (fr) * 1979-01-30 1984-10-15 Otsuka Pharma Co Ltd Procede de determination de la teneur en substances contenant des liaisons glucosidiques associees aux tumeurs, application de ce procede et necessaire pour sa mise en oeuvre.
US4447545A (en) * 1980-11-03 1984-05-08 New England Deaconess Hospital Bladder cancer detection
SU1305556A1 (ru) * 1983-04-18 1987-04-23 Киевский Научно-Исследовательский Институт Туберкулеза И Грудной Хирургии Им.Ф.Г.Яновского Способ определени дифференцирующихс клеток на препарате
EP0254081A2 (fr) * 1986-06-30 1988-01-27 Yuko Yoneda Procédé pour détecter une protéine spécifique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0674177A4 *

Similar Documents

Publication Publication Date Title
CN100472213C (zh) 癌症的检测和治疗
US4940670A (en) Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
Wingard et al. Plasma cholesterol and cancer morbidity and mortality in an adult community
Krop et al. A double blind, randomized, controlled investigation of electrodermal testing in the diagnosis of allergies
EP0674177A4 (fr) Methode de diagnostic des tumeurs malignes chez l'etre humain.
WO1994014071A1 (fr) Methode de diagnostic des tumeurs malignes chez l'etre humain
Markovitz Chromogens in the urine of normal individuals and of epileptic patients which react with Ehrlich's aldehyde reagent
JP2006501447A (ja) 腫瘍学的な諸疾患を診断する方法並びにデバイス
JP2022104553A (ja) ＬＩＰに基づいてＵＭＯＤを修飾した尿中のＮｅｕ５Ｇｃを識別する尿路上皮癌の検査用キット、およびその製造方法
Hein et al. Self-detection of a breast mass in adolescent females
Salo et al. False-positive serological test for syphilis in pregnancy.
Ernst et al. Diagnostic methods in complementary medicine. Which craft is witchcraft?
Hackett et al. Serum detection of carcinoma
RU2077051C1 (ru) Способ диагностики злокачественных опухолей человека
RU2085946C1 (ru) Способ диагностики онкологического заболевания
RU2085945C1 (ru) Способ диагностики онкологического заболевания
RU2079137C1 (ru) Способ диагностики аллергии немедленного типа
RU2027193C1 (ru) Способ диагностики аллергии
Woodhouse The chemodiagnosis of malignancy
UA31359C2 (uk) Спосіб діагностики злоякісних пухлин людини
RU2137420C1 (ru) Способ выявления "группы опухолевого риска" и скрининга ранних стадий опухолевых заболеваний
Zick et al. Plasma based biomarkers detect radiation induced neurotoxicity in cancer patients treated for brain metastasis: A Pilot study.
RU2088136C1 (ru) Способ экспресс-диагностики аденомы щитовидной железы
Fajardo-Ordóñez et al. Correlation between levels of prostate specific antigen and SUVmax values in patients with prostate cancer evaluated with 68Ga-PSMA PET/CT
Taha et al. Brucellar Spondylitis causes Alteration in Serum protein and Electrophoretic pattern

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR BY CA CZ FI GB HU JP KR KZ NO PL UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: AU,BY,CZ,GB,KZ,UA

WWE Wipo information: entry into national phase

Ref document number: 1994904064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08454208

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1994904064

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994904064

Country of ref document: EP